Literature DB >> 25770487

Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

Eliezer M Van Allen1, Levi A Garraway1, Jonathan E Rosenberg2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25770487     DOI： 10.1016/j.eururo.2015.02.044

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  4 in total

Review 1.  Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.

Authors:  Metin Kurtoglu; Nicole N Davarpanah; Rui Qin; Thomas Powles; Jonathan E Rosenberg; Andrea B Apolo
Journal:  Clin Genitourin Cancer       Date:  2015-03-05       Impact factor: 2.872

2.  Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

Authors:  Alexander S Baras; Nilay Gandhi; Enrico Munari; Sheila Faraj; Luciana Shultz; Luigi Marchionni; Mark Schoenberg; Noah Hahn; Mohammad Obaidul Hoque; Mohammad Hoque; David Berman; Trinity J Bivalacqua; George Netto
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

Review 3.  Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer.

Authors:  Isuru S Jayaratna; Neema Navai; Colin P N Dinney
Journal:  Transl Androl Urol       Date:  2015-06

4.  Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer-is it a surrogate for molecular subtypes?

Authors:  Tibor Szarvas; Csilla Olah; Henning Reis
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.